Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Cited In for PubMed (Select 21354971)

1.

Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis.

Haider L.

Oxid Med Cell Longev. 2015;2015:725370. doi: 10.1155/2015/725370. Epub 2015 May 27. Review.

2.

Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.

Wang Q, Chuikov S, Taitano S, Wu Q, Rastogi A, Tuck SJ, Corey JM, Lundy SK, Mao-Draayer Y.

Int J Mol Sci. 2015 Jun 17;16(6):13885-907. doi: 10.3390/ijms160613885.

3.

Cell type-specific Nrf2 expression in multiple sclerosis lesions.

Licht-Mayer S, Wimmer I, Traffehn S, Metz I, Brück W, Bauer J, Bradl M, Lassmann H.

Acta Neuropathol. 2015 Aug;130(2):263-77. doi: 10.1007/s00401-015-1452-x. Epub 2015 Jun 19.

4.

Does Nrf2 help nerves to survive?

Ruprecht K, Paul F.

Neurol Neuroimmunol Neuroinflamm. 2015 May 14;2(3):e105. doi: 10.1212/NXI.0000000000000105. eCollection 2015 Jun. No abstract available.

5.

Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.

Zhao X, Sun G, Zhang J, Ting SM, Gonzales N, Aronowski J.

Stroke. 2015 Jul;46(7):1923-8. doi: 10.1161/STROKEAHA.115.009398. Epub 2015 May 14.

PMID:
25977275
6.

Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2.

Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Márkus NM, Baxter P, Deighton RF, Serio A, Bilican B, Chowdhry S, Meakin PJ, Ashford ML, Wyllie DJ, Scannevin RH, Chandran S, Hayes JD, Hardingham GE.

Nat Commun. 2015 May 13;6:7066. doi: 10.1038/ncomms8066.

7.

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.

Huang H, Taraboletti A, Shriver LP.

Redox Biol. 2015 Apr 29;5:169-175. doi: 10.1016/j.redox.2015.04.011. [Epub ahead of print]

8.

Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.

Parodi B, Rossi S, Morando S, Cordano C, Bragoni A, Motta C, Usai C, Wipke BT, Scannevin RH, Mancardi GL, Centonze D, Kerlero de Rosbo N, Uccelli A.

Acta Neuropathol. 2015 Aug;130(2):279-95. doi: 10.1007/s00401-015-1422-3. Epub 2015 Apr 29.

9.

Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis.

Metz I, Traffehn S, Straßburger-Krogias K, Keyvani K, Bergmann M, Nolte K, Weber MS, Bartsch T, Gold R, Brück W.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 2;2(3):e99. doi: 10.1212/NXI.0000000000000099. eCollection 2015 Jun. No abstract available. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2015 Jun;2(3):e116.

10.

No quiet surrender: molecular guardians in multiple sclerosis brain.

Steinman L.

J Clin Invest. 2015 Apr;125(4):1371-8. doi: 10.1172/JCI74255. Epub 2015 Apr 1. Review.

PMID:
25831441
11.

Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis.

Tannahill GM, Iraci N, Gaude E, Frezza C, Pluchino S.

Front Immunol. 2015 Mar 11;6:106. doi: 10.3389/fimmu.2015.00106. eCollection 2015. Review.

12.

Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.

Brennan MS, Matos MF, Li B, Hronowski X, Gao B, Juhasz P, Rhodes KJ, Scannevin RH.

PLoS One. 2015 Mar 20;10(3):e0120254. doi: 10.1371/journal.pone.0120254. eCollection 2015.

13.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.

Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R.

Ann Clin Transl Neurol. 2015 Feb;2(2):103-18. doi: 10.1002/acn3.148. Epub 2014 Dec 4.

14.

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.

15.

Treatment With Dimethyl Fumarate Attenuates Calcineurin Inhibitor-induced Nephrotoxicity.

Takasu C, Vaziri ND, Li S, Robles L, Vo K, Takasu M, Pham C, Liu S, Farzaneh SH, Foster CE 3rd, Stamos MJ, Ichii H.

Transplantation. 2015 Jun;99(6):1144-50. doi: 10.1097/TP.0000000000000647.

PMID:
25710612
16.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators.

Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13.

17.

Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.

Bomprezzi R.

Ther Adv Neurol Disord. 2015 Jan;8(1):20-30. doi: 10.1177/1756285614564152. Review.

18.

Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.

Apostolova N, Victor VM.

Antioxid Redox Signal. 2015 Mar 10;22(8):686-729. doi: 10.1089/ars.2014.5952.

19.

Dimethyl fumarate ameliorates acute pancreatitis in rodent.

Robles L, Vaziri ND, Li S, Takasu C, Masuda Y, Vo K, Farzaneh SH, Stamos MJ, Ichii H.

Pancreas. 2015 Apr;44(3):441-7. doi: 10.1097/MPA.0000000000000275.

PMID:
25486529
20.

Nrf2 regulates ROS production by mitochondria and NADPH oxidase.

Kovac S, Angelova PR, Holmström KM, Zhang Y, Dinkova-Kostova AT, Abramov AY.

Biochim Biophys Acta. 2015 Apr;1850(4):794-801. doi: 10.1016/j.bbagen.2014.11.021. Epub 2014 Dec 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk